US FDA Guidance Production May Be Slowed By New OMB Review Requirement
White House says all guidances, as well as proposed rules, must be submitted to OMB for a determination whether they are major or minor.
You may also be interested in...
US FDA's efforts to enforce against regenerative medicine and other gray market products might be collateral damage in Trump administration's latest attack on the perceived abuse of powers by regulatory agencies.
Biosimilar supplement approvals by the US FDA take on average about five months as sponsors request easier and quicker ways to update labels.
In an exclusive interview, Center for Drug Evaluation and Research Director Janet Woodcock contends that industry concerns about FDA's new suffix policy aren't reflective of real-world problems.